Innovotech's MBEC Assay(TM) Approved as International Biofilm Standard
April 21 2011 - 8:00AM
Marketwired
Innovotech Inc. (TSX VENTURE: IOT), a pioneer in the field of
biofilm product development, today announced that its MBEC Assay™
has been approved as an ASTM International (ASTM) standard. The
Assay was validated for testing the effectiveness of hard surface
disinfectants formulated to kill biofilm. The MBEC Assay™ is a
biofilm growth device, which allows for the rapid, reproducible and
simultaneous evaluation of multiple test conditions against
microorganisms in their natural, biofilm state.
"Currently, most disinfectants are evaluated using bacteria
grown in suspension," said Dr. Darla M. Goeres, Assistant Research
Professor, Center for Biofilm Engineering (CBE) at Montana State
University, and a member of the ASTM Subcommittee E35 on
Pesticides, Antimicrobials, and Alternative Control Agents. "This
method enables companies to determine the efficacy of products
against bacteria in their more natural state, and therefore
provides a better approach for predicting the efficacy of
disinfectants under real-use conditions."
"The approval of the MBEC Assay™ as an ASTM standard represents
a fundamental shift in how disinfectants will be evaluated on their
effectiveness in protecting against harmful microorganisms," said
Ken Boutilier, President and CEO of Innovotech. "This approval
paves the way for a new generation of disinfectants in the food
industry and in hospitals, designed specifically to address the
issue of biofilms, thereby reducing the number of deaths and
sicknesses resulting from foodborne and infection related
illnesses."
Biofilms are organized communities of microorganisms that exist
in virtually every natural environment. Biofilms can be up to 1000
times more resistant to treatment than the same organism in a
free-floating state.
A recent report indicated that there are 76 million food related
illness a year, resulting in 325,000 hospitalizations and 5,000
deaths in the US, at a cost to the economy of $152 billion a
year.
In addition to its MBEC Assay™, Innovotech sells diagnostic kits
that test bacterial susceptibility against antibiotics under
biofilm conditions.
About ASTM International
ASTM International (formerly American Society for Testing and
Materials) provides a global forum for the development and
publication of international voluntary consensus standards for
materials, products, systems and services. Known for their high
technical quality and market relevance, ASTM standards are used in
research and development, product testing and quality systems. ASTM
standards are a critical element of the information infrastructure
that guides manufacturing and trade in the global economy. For more
information visit http://www.astm.org/
About Innovotech Inc.
Innovotech Inc. is a pioneer in the field of biofilm product
development, focused on providing innovative and practical
solutions to medical, agricultural and industrial problems caused
by microbial biofilms. Biofilms are responsible for a host of
diseases both in human health and agriculture due to their inherent
resistance to existing antibiotics and disinfectants. Aside from
Innovotech's products there are currently no antibiotics,
disinfectants, or diagnostics designed specifically for
biofilm-forming organisms.
Innovotech currently has two commercial products, the MBEC
Assay™ and bioFILM PA™, and one product, Agress®, in advanced
stages of development. The MBEC Assay™ is a high throughput biofilm
growth device. bioFILM PA™ is the first diagnostic kit to assist
physicians in the selection of the most effective combination
antibiotic treatment of patients with biofilm-based chronic lung
infections and Agress® is a unique, environmentally friendly seed
treatment and plant spray designed to protect crops against both
bacterial and fungal infections.
Connect with us:
Website: www.innovotech.ca
Blog: www.cf-test.ca
Twitter:www.twitter.com/innovotech
Facebook:www.facebook.com/innovotech
This document may contain forward-looking statements that are
predictive in nature and subject to risks and uncertainties that
cannot be predicted or quantified; consequently, actual results may
differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or
contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of
predicting regulatory outcomes; changes in the value of the
Canadian dollar; the Company's reliance on a small number of
customers including government organizations; fluctuations in
operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and
potential costs associated with its defense; the Company's exposure
to lawsuits and other matters beyond the control of management.
Should known or unknown risks or uncertainties materialize, or
should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company
undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable
law.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Innovotech Inc. Ken Boutilier President and CEO (780)
448-0585 ext. 221 (780) 424-0941 (FAX) ken.boutilier@innovotech.ca
Innovotech Inc. Amanda Stadel Communications Officer (780) 448-0585
ext. 224 (780) 424-0941 (FAX) amanda.stadel@innovotech.ca
www.innovotech.ca
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024